Begin typing your search...
Biocon opens first manufacturing plant in US
image for illustrative purpose
New Delhi: Indian biopharmaceutical company Biocon on Thursday announced the opening of its first manufacturing plant in the US.
The US-FDA-approved facility, operated by Biocon’s wholly-owned subsidiary Biocon Generics and based in Cranbury, New Jersey, produces oral solid dosage medications with an annual capacity of 2 billion tablets.
The company had acquired the plant from Eywa Pharma in 2023 and invested over $30 million in upgrades to create the state-of-the-art facility.
